Zobrazeno 1 - 10
of 11 344
pro vyhledávání: '"partial agonist"'
Autor:
Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi
Publikováno v:
Neuropsychopharmacology Reports, Vol 44, Iss 1, Pp 187-196 (2024)
Abstract The rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine D2 receptor partial agonist. A multicent
Externí odkaz:
https://doaj.org/article/2fed201989d94c148066160228242cc7
Autor:
Jameson, Adam, Faisal, Muhammad, Fylan, Beth, Bristow, Greg C., Sohal, J., Dalton, C., Sagoo, G.S., Cardno, A.G., McLean, Samantha
Yes
Background: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual’s genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the
Background: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual’s genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the
Externí odkaz:
http://hdl.handle.net/10454/19915
Autor:
Burcu Temizoz, Takayuki Shibahara, Kou Hioki, Tomoya Hayashi, Kouji Kobiyama, Michelle Sue Jann Lee, Naz Surucu, Erdal Sag, Atsushi Kumanogoh, Masahiro Yamamoto, Mayda Gursel, Seza Ozen, Etsushi Kuroda, Cevayir Coban, Ken J. Ishii
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a mouse-selective stimulator of interferon gene (STING) agonist exerting STING-dependent anti-tumor activity. Although DMXAA cannot fully activate human STING, DMXAA reached phase III in lung cancer cli
Externí odkaz:
https://doaj.org/article/96d6c342ff5a4b34983c9c8d51741ae6
Publikováno v:
Nature and Science of Sleep, Vol Volume 15, Pp 779-784 (2023)
Elliott Kyung Lee,1,2 Naomi Spitale,2,3 Rebecca Robillard2 1Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada; 2Sleep Research Unit, Institute for Mental Health Research (IMHR), Ottawa, Ontario, Canada; 3Department of Medicine,
Externí odkaz:
https://doaj.org/article/a274a5d68d0147b383e0e04ef68bf08c
Publikováno v:
Schizophrenia Research: Cognition, Vol 34, Iss , Pp 100290- (2023)
Background: In a previous meta-analysis, the use of serotonin1A(5-HT1A) receptor partial agonists of the azapirone class as an add-on therapy was associated with beneficial effects on positive symptoms and attention/processing speed in schizophrenia
Externí odkaz:
https://doaj.org/article/aad37bd6c23d4f1386d2b37390a92559
Publikováno v:
Frontiers in Psychiatry, Vol 14 (2023)
Low doses of μ-opioid receptor (MOR) agonists rapidly ameliorate symptoms in treatment-resistant obsessive–compulsive disorder (OCD) patients (10–50% of OCD patients). However, the utility of MOR agonists is limited by their safety liabilities.
Externí odkaz:
https://doaj.org/article/91ab2b9b4d3a4e0fbea1663e2b080e0b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lluis Niell Galmes, Elmars Rancans
Publikováno v:
Frontiers in Psychiatry, Vol 14 (2023)
Real-world evidence fills in an important gap by providing data on the effectiveness and tolerability of new medications in everyday patients. In this data collection form a Spanish hospital, the effectiveness and tolerability of cariprazine were eva
Externí odkaz:
https://doaj.org/article/036cab063b8c4af7bcc0f2155b5d58a8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.